Scholar Rock (SRRK) Expected to Announce Quarterly Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.8405) per share and revenue of $3.3330 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the previous year, the company posted ($0.67) earnings per share. On average, analysts expect Scholar Rock to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Scholar Rock Price Performance

Shares of SRRK opened at $45.85 on Tuesday. The stock has a 50 day simple moving average of $50.06 and a 200 day simple moving average of $47.74. Scholar Rock has a 52-week low of $27.07 and a 52-week high of $58.49. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. The firm has a market capitalization of $5.49 billion, a PE ratio of -12.77 and a beta of 0.69.

Insiders Place Their Bets

In other Scholar Rock news, Director Katie Peng sold 5,446 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $293,430.48. Following the transaction, the director directly owned 34,301 shares of the company’s stock, valued at $1,848,137.88. This represents a 13.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the sale, the director owned 27,856 shares of the company’s stock, valued at $1,500,881.28. This trade represents a 9.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 17,149 shares of company stock worth $923,108 in the last three months. Insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently made changes to their positions in SRRK. California State Teachers Retirement System boosted its position in Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after buying an additional 577 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Scholar Rock by 25.1% during the fourth quarter. Osaic Holdings Inc. now owns 3,318 shares of the company’s stock worth $146,000 after buying an additional 665 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Scholar Rock during the fourth quarter worth $30,000. Summit Securities Group LLC bought a new position in shares of Scholar Rock in the 4th quarter valued at $31,000. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Scholar Rock by 6.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company’s stock valued at $395,000 after acquiring an additional 710 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SRRK shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Friday, July 17th. HC Wainwright increased their price objective on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wedbush reaffirmed an “outperform” rating and issued a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday, July 21st. Barclays upped their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $56.21.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).